BioMarin Pharmaceutical
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The c...
Latest News
17 hours ago · marketbeat.com
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion LoomsBioMarin Pharmaceutical NASDAQ: BMRN expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hardy said at the UBS Global Biopharma Conference.
18 hours ago · seekingalpha.com
BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 TranscriptBioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript
5 days ago · marketbeat.com
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease PipelineBioMarin Pharmaceutical NASDAQ: BMRN is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a company discussion.
5 days ago · seekingalpha.com
BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptBioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
13 days ago · seekingalpha.com
BioMarin: Better Risk-Reward Ahead Of Three FDA DecisionsBioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, and a full approval would further strengthen BMRN's existing achondroplasia franchise. Their Amicus acquisition also brings new revenue sources, though I reckon it remains to be seen if it fully justifies the debt required to finance the transaction.
13 days ago · prnewswire.com
BioMarin to Participate in Upcoming Investor ConferencesStifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.
14 days ago · seekingalpha.com
BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call TranscriptBioMarin Pharmaceutical Inc. ( BMRN ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Brian Mueller - CFO & Executive VP of Finance Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Eliana Merle - Barclays Bank PLC, Research Division Adithya Jayaraman - Evercore Inc. Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Alexandria Hammond - Wolfe Research, LLC Rakesh Kumar Joon Lee Olivia Brayer - Cantor Fitzgerald & Co., Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the BioMarin Third Quarter 2026 Conference Call.
14 days ago · marketbeat.com
BioMarin Pharmaceutical Q3 Earnings Call HighlightsBioMarin Pharmaceutical NASDAQ: BMRN reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic conditions business grew 44%.
14 days ago · zacks.com
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
14 days ago · zacks.com
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass EstimatesBioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BMRN